H. Reiser

Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy

Rishi P. Singh, B. Mukesh, G. Staurenghi, 2016, British Journal of Ophthalmology.

Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery.

H. D. Cavanagh, W. A. Maxwell, T. Walters, 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy

Rishi P. Singh, G. Jaffe, K. Sall, 2012, Clinical ophthalmology.

Once‐daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: Phase 3 study

Satish S. Modi, B. Philipson, C. Traverso, 2014, Journal of cataract and refractive surgery.

Retinal oxygen consumption in vitro the effect of diabetes mellitus, oxygen and glucose

E. Stefánsson, D. Hatchell, D L Hatchell, 1990, Acta ophthalmologica.

Clinical outcomes in a U.S. registration study of a new EDOF intraocular lens with a nondiffractive design

D. Koch, Srichand Jasti, John P Berdahl, 2022, Journal of cataract and refractive surgery.

Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.

B. Joondeph, J. Pearlman, C. Wykoff, 2023, JAMA ophthalmology.

0.2% Betamethasone Sodium Phosphate: A Multicenter, Randomized, Double-Masked Study to Compare Its Ocular Safety, Tolerability, and Efficacy to Vehicle in Cataract Surgery Subjects

R. Lindstrom, K. Hosseini, S. Gollamudi, 2023, Clinical ophthalmology.